Olmutinib
Olmutinib was a Korean-developed EGFR pill approved in South Korea in 2016 for lung cancers that had developed the T790M resistance mutation, the same niche as osimertinib; severe skin reactions and osimertinib's success ended its development.
Overview
Hanmi Pharmaceutical's olmutinib became the first third-generation EGFR inhibitor to reach any market when South Korea's Ministry of Food and Drug Safety approved it in May 2016 for T790M-positive non-small cell lung cancer after first-line EGFR therapy. Boehringer Ingelheim licensed it worldwide but returned the rights within months after reports of fatal toxic epidermal necrolysis and Stevens-Johnson syndrome and after osimertinib's phase 3 results. Hanmi ended development in 2018 and the drug is no longer marketed. It is remembered as a case study in how a first-to-market approval on early data can be overtaken.
A covalent inhibitor that binds cysteine 797 of EGFR and blocks the T790M resistance mutation while sparing the normal receptor. Connects to EGFR.
1.Olmutinib slips into a pocket on EGFR.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Olmutinib" OR ABSTRACT:"Olmutinib" OR TITLE:"Olita" OR ABSTRACT:"Olita" OR TITLE:"HM61713" OR ABSTRACT:"HM61713" OR TITLE:"BI 1482694" OR ABSTRACT:"BI 1482694") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Olmutinib, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentPorfimer sodium
Shares Non-small-cell lung cancer and the tag chembl-universe.
- TreatmentNimotuzumab
Shares EGFR and the tag chembl-universe.
- TreatmentOlaratumab
Shares Small-molecule kinase inhibitors and the tag chembl-universe.
- TreatmentNedaplatin
Shares Non-small-cell lung cancer and the tag chembl-universe.
- TreatmentInfigratinib
Shares Small-molecule kinase inhibitors and the tag chembl-universe.
- TreatmentVindesine
Shares Non-small-cell lung cancer and the tag chembl-universe.
- TreatmentTrilaciclib
Shares Small-molecule kinase inhibitors and the tag chembl-universe.
- PersonThomas J. Lynch Jr.
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer.